• CDC
  • Heart Failure
  • Cardiovascular Clinical Consult
  • Adult Immunization
  • Hepatic Disease
  • Rare Disorders
  • Pediatric Immunization
  • Implementing The Topcon Ocular Telehealth Platform
  • Weight Management
  • Screening
  • Monkeypox
  • Guidelines
  • Men's Health
  • Psychiatry
  • Allergy
  • Nutrition
  • Women's Health
  • Cardiology
  • Substance Use
  • Pediatrics
  • Kidney Disease
  • Genetics
  • Complimentary & Alternative Medicine
  • Dermatology
  • Endocrinology
  • Oral Medicine
  • Otorhinolaryngologic Diseases
  • Pain
  • Gastrointestinal Disorders
  • Geriatrics
  • Infection
  • Musculoskeletal Disorders
  • Obesity
  • Rheumatology
  • Technology
  • Cancer
  • Nephrology
  • Anemia
  • Neurology
  • Pulmonology

Cardiometabolic Disease Update: 12 Studies

Slideshow

Less than 7% of the US population has optimal cardiometabolic health according to a novel study that assessed 5 key components of the measure. That disappointing metric and others like it have fueled a surge in research into cardiometabolic disease pathophysiology, prevention, and treatment.

Click through the 12 slides in this update for an at-a-glance overview of 2022's most promising cardiometabolic research to date.

CKD, Heart Failure, Hypertension, MACE, NAFLD/NASH, Type 2 Diabetes

Recent Videos
New Research Amplifies Impact of Social Determinants of Health on Cardiometabolic Measures Over Time
Where Should SGLT-2 Inhibitor Therapy Begin? Thoughts from Drs Mikhail Kosiborod and Neil Skolnik
Related Content
The Liver Meeting 2024: Bausch Health Presents Phase 3 Study Design for Investigational Rifaximin Formulation to Delay OHE / Image credit: ©Shidlovski/Shutterstock.com

The Liver Meeting 2024: Bausch Health Presents Phase 3 Study Design for Investigational Rifaximin Formulation to Delay OHE

Sydney Jennings
November 19th 2024
Article

The RED-C clinical trial program highlights the promising potential of the rifaximin soluble solid dispersion immediate-release tablets for delaying early HE-related decompensation.

Navigating Cardiovascular Complications of Obesity: Expert Insights for Primary Care

Navigating Cardiovascular Complications of Obesity: Expert Insights for Primary Care

Sydney Jennings
August 30th 2023
Podcast

Listen to our latest podcast episode for details on top CVD risk factors to screen patients with obesity for, medications to help prevent CVD, and more.

Among Stroke Survivors, GLP-1RAs, SGLT2is May Reduce Risk of Future MI, Recurrent Stroke / image credit American Heart Association

Among Stroke Survivors, GLP-1RAs, SGLT2is May Reduce Risk of Future MI, Recurrent Stroke

Grace Halsey
November 11th 2024
Article

AHA 2024. Study authors reported a 74% lower risk of death and an 84% lower risk of MI among participants taking either a GLP-1RA or an SGLT2i.

Obesity & Type 2 Diabetes: An Expert Discussion

Obesity & Type 2 Diabetes: An Expert Discussion

Sydney Jennings
June 30th 2023
Podcast

In our latest episode, 2 obesity experts discuss the importance of early intervention to reduce risk for complications, suggestions for managing patients in primary care, and more.

New Phase 3 Trials Investigate Survodutide as a Promising Treatment for Obesity / Image credit: ©missbobbit/AdobeStock

New Phase 3 Trials Investigate Survodutide as a Promising Treatment for Obesity

Sydney Jennings
November 6th 2024
Article

SYNCHRONIZE-1 and -2 will provide "robust evidence" on the safety, efficacy, and tolerability of survodutide in adults with obesity with or without T2D.

Semaglutide May Reduce Alzheimer’s Risk in Adults with T2D: Daily Dose / image credit: ©New Africa/AdobeStock

Semaglutide May Reduce Alzheimer’s Risk in Adults with T2D: Daily Dose

Sydney Jennings
November 5th 2024
Article

Your daily dose of the clinical news you may have missed.

© 2024 MJH Life Sciences

All rights reserved.